May 23, 2006 -- Genentech and Roche will restart a trial of Avastin that was temporarily halted due to fears of cardiac side effects; Alza received FDA approval for a novel needle-free treatment of post-op pain; Avanir paid $29 million to acquire privately held Alamo Pharma; DOV Pharma revealed bicifadine was not effective against chronic low back pain; Xoma signed a deal with Schering-Plough to develop therapeutic antibodies; Cyberonics touted a study showing that patients with deep depression were not helped by ordinary therapy; New River Pharma began enrolling adult patients in a study for attention deficit disorder; Immtech received expanded funding from the Gates foundatikon for a sleeping sickness drug; Cephalon will pay $15 million upfront to Pharmacopeia in a drug development deal; Geron said its breast cancer was effective in laboratory tests; two studies showed that Seroquel from AstraZeneca provided a benefit as an adjunct to SSRI/SNRI drugs; and ImaRx filed for its IPO. The Centient Biotech 200™ was down 27 points at 3560.77, a loss of .74%. More details...
